chronic kidney disease

Comparative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Chronic Kidney Disease and Cardiovascular Disease: Integrated Insights from the DANFLU-2 Trial

By MedXY 12/25/2025

The DANFLU-2 trial demonstrates that high-dose influenza vaccine provides superior protection against influenza-related hospitalizations in chronic kidney disease and reduces cardiorespiratory hospitalizations in older adults irrespective of cardiovascular disease status.

Nephrology news

Conservative Kidney Management Versus Dialysis in Older Adults with Kidney Failure: Evidence Is Inconclusive — What Clinicians Should Know

By MedXY 12/15/2025

A 2025 Cochrane review of 24 non-randomised studies (26,127 participants) found very low‑certainty evidence comparing conservative kidney management (CKM) with dialysis in people aged ≥65 with stage 5 chronic kidney disease; survival and quality-of-life differences are uncertain, highlighting the need for individualized decisions and higher-quality research.

Critical Care Nephrology news

Hospital Acute Kidney Injury Strongly Linked to Long-Term Death, Dialysis, and CKD: Meta-Analysis of Matched-Control Studies

By MedXY 12/09/2025

A meta-analysis of 14 matched-control studies (n=1,058,109) finds that survivors of in-hospital AKI face higher long-term mortality, greater subsequent dialysis need, and elevated risk of CKD versus matched controls.

Diabetes & Endocrinology Nephrology news

Empagliflozin Protects the Kidney Across Clinical Spectra — Acute Dip Is Not a Dealbreaker

By MedXY 11/28/2025

An individual participant-level meta-analysis of 23,340 participants shows empagliflozin reduces acute and chronic kidney events, slows eGFR decline, and lowers kidney failure risk regardless of predicted acute eGFR dip, diabetes, heart failure, baseline eGFR, or albuminuria.

Diabetes & Endocrinology Nephrology news

Balcinrenone plus Dapagliflozin Reduces Albuminuria in CKD: MIRO‑CKD Phase 2b Shows Dose‑Dependent Benefit with Acceptable Safety

By MedXY 11/28/2025

The MIRO‑CKD phase 2b trial found that adding the non‑steroidal MRA balcinrenone to dapagliflozin reduced albuminuria versus dapagliflozin alone in people with CKD, with dose‑dependent effects and modest hyperkalaemia rates over 12 weeks.

Internal Medicine Nephrology news

The Vanishing Female Survival Advantage in Stage 5 CKD: Higher Mortality and Lower Receipt of Kidney Replacement Therapy Among Women

By MedXY 11/17/2025

In a population-based Alberta cohort, women with incident stage 5 CKD lost the usual female survival advantage: younger women had substantially higher excess mortality than men and were less likely to receive transplants or dialysis, independent of comorbidity.

Internal Medicine Nephrology news

Clinical Decision Support Tool May Improve ACEI and ARB Use in CKD

By MedXY 11/14/2025

A personalized clinical decision support tool increased 30‑day reinitiation of ACE inhibitors or ARBs from 13% to 18% among veterans with CKD; benefits were modest and limited by population and implementation factors.

Nephrology news

Global CKD Now Affects 788 Million Adults (1990–2023): Rising Prevalence, Growing Mortality, and a Major Cardiovascular Risk

By MedXY 11/11/2025

The GBD 2023 analysis estimates 788 million adults living with chronic kidney disease in 2023, rising since 1990, with CKD a top-10 cause of death and a major contributor to cardiovascular mortality. Urgent action on screening, prevention, and treatment is needed.

Diabetes & Endocrinology Nephrology news

SGLT2 Inhibitors Reduce Kidney Events, Hospitalization and Death Regardless of Diabetes or Albuminuria: A SMART-C Meta-Analysis Interpretation

By MedXY 11/08/2025

A pooled analysis of 58,816 participants shows SGLT2 inhibitors lower kidney disease progression, AKI, hospitalizations, and mortality across diabetes status and albuminuria levels, with larger absolute kidney benefits where UACR ≥200 mg/g.

Diabetes & Endocrinology Nephrology news

SGLT2 Inhibitors Protect Kidneys Across the Spectrum: Benefits Even in Stage 4 CKD and Minimal Albuminuria

By MedXY 11/08/2025

A SMART‑C meta‑analysis of 70,361 participants shows SGLT2 inhibitors reduce CKD progression and kidney failure across eGFR and albuminuria strata, including stage 4 CKD and low albuminuria.

Cardiology Nephrology news

Dapagliflozin and Cardiac Remodeling in Chronic Kidney Disease: New Evidence for Cardioprotection

By MedXY 10/30/2025

Dapagliflozin reduces left ventricular mass index in chronic kidney disease patients, revealing a key mechanism for cardioprotective effects of SGLT2 inhibitors and highlighting early treatment benefits.

Cardiology Pediatrics Specialties Transplantation

Everolimus and Low-Dose Tacrolimus Therapy After Pediatric Heart Transplant: Insights from a Multicenter Randomized Clinical Trial

By MedXY 10/21/2025

This randomized trial evaluates the safety and efficacy of everolimus combined with low-dose tacrolimus versus standard immunosuppression in children 6 months post-heart transplant, highlighting comparable rejection rates, improved kidney function, and reduced CMV infection risk.

Cardiology Nephrology Specialties

Statin Therapy in Older Adults with Chronic Kidney Disease: Primary Prevention of Cardiovascular Disease and Safety Profile in Hypercholesterolemic Patients

By MedXY 10/20/2025

This study demonstrates that statin therapy effectively reduces cardiovascular risk and all-cause mortality in older adults with chronic kidney disease and hypercholesterolemia, without increasing major adverse events, even in very elderly patients.

Diabetes & Endocrinology Nephrology Specialties

Impact of Dietary Patterns on the Progression of Chronic Kidney Disease in Cardio-Metabolic Disorders: Insights from Multi-State Models in a Large UK Cohort

By MedXY 10/19/2025

This study reveals that adherence to the American Heart Association diet significantly reduces CKD progression risk from cardio-metabolic disorders, underscoring its role in early intervention strategies.

Cardiology Nephrology news

Reassessing the Role of Steroidal Mineralocorticoid Receptor Antagonists in Dialysis Patients: Safety and Efficacy Insights from a Systematic Review and Meta-Analysis

By MedXY 10/11/2025

Steroidal mineralocorticoid receptor antagonists show minimal impact on cardiovascular mortality in dialysis patients, with limited safety concerns and evidence gaps in subgroups and non-steroidal agents.

Cardiology Clinical Updates Nephrology

Exploring the Impact of Reduced Left Ventricular Function on Outcomes After PCI in Chronic Kidney Disease Patients

By MedXY 09/27/2025

Reduced left ventricular ejection fraction (LVEF) adversely affects survival and myocardial infarction risk in patients with chronic kidney disease undergoing percutaneous coronary intervention, despite no significant difference in overall major cardiovascular events.

Cardiology Nephrology

Abelacimab Shows Consistent Bleeding Safety Across Kidney Function in Atrial Fibrillation: Insights from the AZALEA-TIMI 71 Trial

By MedXY 09/27/2025

This analysis of the AZALEA-TIMI 71 trial reveals that abelacimab, a novel factor XI inhibitor, significantly reduces bleeding risk versus rivaroxaban in atrial fibrillation patients, regardless of kidney function, suggesting its promise for those with chronic kidney disease.

Clinical Updates Nephrology news

Lubiprostone Therapy in Chronic Kidney Disease: A Phase 2 Trial Reveals Mitochondrial Enhancement via Polyamine Modulation

By MedXY 09/19/2025

A phase 2 randomized trial in CKD patients shows lubiprostone preserves renal function by modulating gut microbiota polyamine pathways and improving mitochondrial health, independent of uremic toxin levels, offering a novel therapeutic avenue.

Nephrology news Specialties

Silent Threats: Why Uremia is Affecting Younger Adults and How to Protect Your Kidneys

By MedXY 08/27/2025

Uremia, the deadly end-stage of kidney disease, is increasingly diagnosed in younger adults. Early detection and lifestyle changes can prevent progression. This article explores risk factors, symptoms, diagnosis, treatment options, and prevention strategies.

Clinical Updates Diabetes & Endocrinology Nephrology news Specialties

Long-Term Kidney Protection with SGLT2 Inhibitors in Type 2 Diabetes and CKD: Insights from the DARWIN-Renal Study

By MedXY 08/23/2025

A large real-world study shows that SGLT2 inhibitors significantly slow kidney function decline and improve albuminuria compared with other glucose-lowering drugs in type 2 diabetes patients with chronic kidney disease.